Artificial intelligence (AI) could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to a new study.
Finding the right antibiotic dose is akin to a Goldilocks problem: give too little, and the infection will persist; too much, and side-effects will override the benefits of the therapy. To get it “just right”, Prof Dr Birgit Koch talks about dosing optimisation in the clinical setting.
Big data is transforming diagnosis and medical care, but the critical challenge remains over how to equally apply the benefits it delivers across real-world clinical settings, according to industry expert Prof Benoît Macq.
Molecular radiotherapy shows great potential in becoming a more mainstream treatment for cancer, but the field is being hampered by a limited radionuclide supply.
Mathematical models used as patient surrogates could help clinicians select the best cancer treatment before going to the patient’s bedside.
After a liver transplant, patients have to take immune-suppressing drugs for the rest of their lives. These so-called immunosuppressants prevent the organ from being rejected. However, the drugs increase the risk of cancer and serious infections. They can also significantly impair kidney function and even lead to dialysis. In order to be able to give those affected as much immunosuppression as…
A team led by the Garvan Institute of Medical Research has revealed a new approach for classifying breast cancer subtypes based on their cell profile, which could help personalise treatments for patients. By analysing breast cancer biopsies from patients at Sydney hospitals, the researchers revealed more than 50 distinct cancer, immune and connective cell types and states, which could assign…
A solid diagnosis has always been the first step on any patient’s journey to health. However, diagnostic categories are necessarily oversimplifications. In the last decades, medical professionals and scientists have begun to uncover the true variability in patients’ physiological and biochemical make-up that is the principal cause for individual variations in the way diseases present…
To avoid adverse reactions, personalised laboratory medicine can help to predict a patient’s drug response. Investigations based on DNA and other omics technologies – e.g. genomics, transcriptomics, proteomics, metabolomics – along with microarray technologies, is making a particularly valuable contribution to cancer care, in which personalised approaches are becoming possible through…
A new study from the University of Helsinki shows that cells that are freshly isolated from lung cancers can be used to create robust drug response data. This approach can identify actionable or non-responsive treatments, illustrated by a case study in which the assay was used to guide the compassionate treatment of a patient.
Cancer patients’ medical records can often comprise up to 100 terabytes of individual — and usually very heterogeneous — data, including blood and tumor values, personal indicators, sequencing and treatment data, and much more besides. Up to now, it has been virtually impossible to use this wealth of information efficiently due to a lack of appropriate processing mechanisms. As a result,…
El laboratorio de Genómica Biomédica del IRB Barcelona (Institute for Research in Biomedicine) ha desarrollado un método computacional que identifica las mutaciones causantes del cáncer para cada tipo de tumor.
The Biomedical Genomics laboratory at the Institute for Research in Biomedicine (IRB) Barcelona has developed a computational tool that identifies cancer driver mutations for each tumour type. This and other developments produced by the same lab seek to accelerate cancer research and provide tools to help oncologists choose the best treatment for each patient. The study has been published in the…
The Netherlands Cancer Institute, University of Amsterdam (UvA), and Elekta will collaborate on the development of new AI strategies for the further improvement of precision radiotherapy. This concerns the personalization of treatment by improving the quality of imaging used during treatment, predicting and accounting for changes in the patient’s anatomy over time, and automatically adapting…
Integrating laboratory functions on a microchip circuit is helping improve the cost-effectiveness of drug development. So-called ‘lab-on-a-chip’ or ‘human-on-a-chip’ technology can highlight which treatments may, or may not, work before advancing along the clinical trial process. It can also have benefits for chronic and rare diseases, as well as helping shape personalised medicine.…
Intrahepatic cholangiocarcinoma (ICC) develops within the liver. With one to two cases per 100,000 inhabitants in Germany, ICC is one of the rare diseases overall, but it is the second most common liver cancer. The aggressive bile duct tumour remains clinically inconspicuous for a long time, so that it is often only detected late. Because the tumour also only responds to chemotherapy to a limited…
Women with incident and proliferative benign breast diseases (BBD) are likelier to develop breast cancer, a Spanish researcher explained during the 12th European Breast Cancer Conference in October. These findings support the idea of designing personalised breast cancer screening strategies to improve effectiveness.
As people get older they often jump from disease to disease and carry the burden of more chronic diseases at once. But is there a system in the way diseases follow each other? Danish researchers have for the past six years developed a comprehensive tool, the Danish Disease Trajectory Browser, that utilizes 25 years of public health data from Danish patients to explore what they call the main…
Siri and Alexa are leading the way: the virtual assistants meet many daily needs. Soon, similarly programmed software and a ‘digital patient twin’, will be launched into the medical world – both IT applications based on Artificial Intelligence (AI). The virtual medical assistant and digital patient twin are two key aspects of a research project ‘Models for Personalised Medicine’.…
Engineers in the US have demonstrated that drug levels inside the body can be tracked in real time using a custom smartwatch that analyzes the chemicals found in sweat. This wearable technology could be incorporated into a more personalized approach to medicine — where an ideal drug and dosages can be tailored to an individual. The engineers at the University of California, Los Angeles (UCLA)…
In recent years, technological and regulatory advances have made digital pathology a viable alternative to the conventional microscope. The obtention of a digital replica of the traditional glass slide and its use for primary diagnosis has revolutionized pathology and is shaping the future of the discipline. A digital pathology lab uses digital histology slides for routine diagnosis, and these…
A new joint report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) presents the largest venture ever on precision medicine in diabetes. The report includes a detailed overview and roadmap for how this new approach to diabetes medicine can be evaluated and implemented into clinical practice.
Computational pathology has increased applications for diagnosis, prediction of prognosis and therapy response, facilitating the movement of healthcare towards personalised medicine. Coupled with deep learning, such tools are ever more efficient and robust within research and clinical settings. The growing role of computational pathology was highlighted by Professor Andrew Janowczyk at the…
BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, announced a collaboration with Charité – Universitätsmedizin Berlin under the recently established SyMBoD consortium. Under the agreement, BellaSeno will design and manufacture personalized, 3D-printed, absorbable implants suitable for the treatment of diabetes patients with bone defects. The…
Liquid biopsy offers a new dimension to detection and stratification of cancer – yet the technique also faces hurdles in becoming a mainstream diagnostic approach for more personalised treatments. A critical challenge lies in identifying the extremely low concentrations of the bio-analytes of CTC (circulating tumour cells), ctDNA (circulating tumour DNA) and exosomes in the blood.